Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

BB Biotech AG publishes its interim report

21.04.2023

Ad hoc announcement pursuant to Art. 53 LR

BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2023, which covers the results of its business activities for the first three months of 2023.

Based on the consolidated accounts of BB Biotech AG, net loss for the period ended March 31, 2023 amounted to CHF 254 mn (loss of CHF 300 mn in the same period 2022). For an investment company, the results reflect the share price development of the companies held in the portfolio.

The interim report as at March 31, 2023, is available under report.bbbiotech.ch/Q123 or www.bbbiotech.com.

 

For further information:

Media Relations
Bellevue Asset Management AG
Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch